KPRX Stock Overview
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Kiora Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.48 |
| 52 Week High | US$5.25 |
| 52 Week Low | US$0.45 |
| Beta | -0.26 |
| 1 Month Change | -21.31% |
| 3 Month Change | -16.64% |
| 1 Year Change | -89.94% |
| 3 Year Change | -99.71% |
| 5 Year Change | -99.70% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Oct 13Kiora Pharma announces 1-for-40 reverse stock split
Sep 26Kiora Pharmaceuticals reports 1H results
Aug 12Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing
Jul 28Kiora Pharmaceuticals prices $5.2M underwritten public offering
Jul 22Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201
Jul 05EyeGate Pharmaceuticals announces $8M private placement
Jan 06EyeGate surge in premarket as it acquires Panoptes Pharma for $4M
Dec 21Shareholder Returns
| KPRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.9% | -0.6% | 1.0% |
| 1Y | -89.9% | 10.6% | 21.9% |
Return vs Industry: KPRX underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: KPRX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| KPRX volatility | |
|---|---|
| KPRX Average Weekly Movement | 21.0% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KPRX's share price has been volatile over the past 3 months.
Volatility Over Time: KPRX's weekly volatility has increased from 15% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 12 | Brian Strem | www.kiorapharma.com |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair.
Kiora Pharmaceuticals, Inc. Fundamentals Summary
| KPRX fundamental statistics | |
|---|---|
| Market cap | US$12.60m |
| Earnings (TTM) | -US$13.04m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs KPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KPRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$4.03m |
| Gross Profit | -US$4.03m |
| Other Expenses | US$9.02m |
| Earnings | -US$13.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KPRX perform over the long term?
See historical performance and comparison